Back to search results

Study of ARC101 in Advanced Solid Tumors

This study is testing a new drug called ARC101 in people with advanced solid tumors, specifically ovarian, testicular, or other cancers that are Claudin 6 positive. The main goals are to see how safe ARC101 is, what side effects it might cause (dose-limiting toxicities and adverse events), and how well your body handles it. Researchers will also look for any signs that ARC101 is helping to shrink the cancer. You might be able to join if you are 18 or older, have advanced cancer that can be measured, and are generally well enough for treatment. This study is currently recruiting about 70 participants, but its exact status is unclear.

Study design
This is a first-in-human study involving about 70 participants with advanced solid tumors. It will test the drug ARC101.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your health will be monitored for side effects and laboratory values for up to 100 days after your last dose of ARC101.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06672185

ARC101 in Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Third Arc Bio
~70 participants
Updated 2026-08-27 on ClinicalTrials.gov
What's tested:ARC101

At a glance

Recruiting sites
12 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency and type of dose-limiting toxicities.
Measured over Day 1-Day 21 of the first treatment cycle
+1 more outcome measured

Conditions

Advanced Solid Tumor

Explore related trials

Malignant Ovarian NeoplasmMalignant Testicular NeoplasmSolid NeoplasmClaudin-6

Where it's being run

13 sites across 10 states
Israel3
Quebec2
Massachusetts1
Michigan1
Texas1
Queensland1
South Australia1
Victoria1

Who to contact

VP Clinical Operations
[email protected]
267-589-9444
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Locally advanced or metastatic solid tumor ovarian, testicular or other Claudin 6+ cancers
Measurable or evaluable disease, per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Adequate organ function

Exclusion

Active CNS involvement
Malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study drug.
Presence of uncontrolled ascites
Toxicity related to prior anticancer therapy that has not returned to Grade ≤1 or baseline levels
Clinically significant pulmonary compromise
Active autoimmune disease within 12 months prior to first dose of study drug.
Female participant who is pregnant, breastfeeding, or plans to become pregnant or male participant who plans to father a child either while enrolled or within 90 days after the final administration of study drug.

What this trial measures

  • Frequency and type of dose-limiting toxicities.Day 1-Day 21 of the first treatment cycle
  • Occurrence and severity of adverse events, serious adverse events and laboratory values.Day 1 to 100 days after the last dose of study drug.